An equivocal HER2 breast cancer result: what to clarify

An “equivocal” HER2 result needs interpretation within the complete laboratory assessment. The word does not automatically establish eligibility for a medicine or rule out treatment options. Before seeking another opinion, obtain the full report and ask whether the laboratory work-up has been completed. A photograph of one line is not enough to choose a treatment.

Check whether the report is final

A pathology record may contain separate morphology, immunohistochemistry and additional-test sections. An initial report can be followed by an addendum under the same specimen number. Ask whether any supplementary results remain outstanding, and preserve the original documents. A translation should reproduce the method and result accurately rather than silently changing an unfamiliar classification into a simpler one.

In breast cancer, HER2 is considered alongside hormone receptors and other disease characteristics. The National Cancer Institute explains that these biomarkers inform treatment planning. A particular marker may support certain targeted options, but the choice also depends on the clinical setting. NCI: How Breast Cancer Is Diagnosed.

Understand why the testing method matters

Tests may assess the HER2 protein or gene-related findings. They measure different things that the laboratory interprets using established criteria. Where an immunohistochemical finding requires clarification, the oncologist and pathologist determine the appropriate additional assessment. Ordering a broad set of tests independently may consume tissue without resolving the question that actually matters.

Ask for four points in plain language: which method was used, what it showed, whether the HER2 status is considered resolved and which treatment decision remains open. This distinguishes incomplete testing from a disagreement about interpretation. If two centres report different conclusions, they need the full records and comparable specimen information, not only the final positive or negative labels.

Identify the tissue and its place in the timeline

Record the collection date, anatomical site, specimen type and laboratory number. A sample from the original tumour, tissue removed after systemic treatment and a biopsy of recurrence represent different points in the illness. Do not replace a recent result with an older one simply because the older file is easier to send. Keep both so the specialist can assess the reason for a difference.

NCI notes that tumour biomarkers can change over time and that a test reflects the sampled material at a particular moment. That does not mean everyone needs another biopsy. Its necessity, safety and expected contribution require an individual clinical decision. NCI: Biomarker Testing for Cancer Treatment.

Connect the classification to the proposed treatment

If a preliminary plan already names a medicine, ask which result supports that recommendation and whether further HER2 clarification could change it. Categories used in current research and drug indications should not be treated as interchangeable with a simple positive-versus-negative label. The oncologist should explain which category matters for the proposed option, disease stage and previous treatment history.

A matching biomarker does not guarantee that a medicine will work. Clinical suitability, contraindications, availability at the receiving hospital and follow-up arrangements are separate questions. Laboratory information should therefore feed into the treating team’s decision. Do not change prescribed treatment because of an isolated result or an online interpretation.

Arrange a specimen review with a clear purpose

Before sending slides or blocks, confirm exactly what the receiving laboratory requires, how the material will be tracked and whether it will be returned. Establish whether a report review is sufficient for the initial opinion or whether the pathologist needs the specimen itself. The answer can prevent unnecessary shipment or avoid a consultation that cannot resolve the issue.

The guides to pathology review and biomarker-testing questions explain these practical steps. The useful outcome is a documented interpretation, an explanation of any remaining uncertainty and a named next clinical decision. A longer list of tests is not a substitute for that explanation.